Jozef Urdzik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jozef Urdzik has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Anders Nilsson
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
1 shared publicationBengt Isaksson
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
1 shared publicationBritt-Marie Karlson
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
1 shared publication- Cecilia Strömberg
Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
1 shared publication - Christopher Månsson
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
1 shared publication - Evgeniya Mickols
Department of Pharmacy, Uppsala University
1 shared publication
Latest Publications
- Open Access
- 15 May 2019
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 39 (5) , 2509-2512
Percutaneous Irreversible Electroporation as First-line Treatment of Locally Advanced Pancreatic Cancer
Background/Aim: Irreversible electroporation (IRE) has recently been used as an experimental ablation treatment following systemic chemotherapy in locally advanced pancreatic cancer (LAPC). The primary aim of this study was to evaluate survival of LAPC patients after IRE prior to chemotherapy. The secondary aim was to examine the complication rates. Patients and Methods: Twenty-four patients with LAPC were included and treated with percutaneous ultrasound-guided IRE under general anesthesia. Survival data from the National Quality Registry for Pancreatic and Periampullary Cancer for LAPC during the same period were used for comparison. Results: The median survival after diagnosis was 13.3 months in the IRE group compared to 9.9 months in the registry group (p=0.511). Six patients had a severe complication after IRE treatment. Conclusion: No obvious gain in survival was observed with IRE as the first line treatment of LAPC and IRE was associated with severe complications. This study does not support percutaneous IRE in this setting.
- 15 May 2019
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 39 (5) , 2509-2512
Open AccessPercutaneous Irreversible Electroporation as First-line Treatment of Locally Advanced Pancreatic Cancer
Background/Aim: Irreversible electroporation (IRE) has recently been used as an experimental ablation treatment following systemic chemotherapy in locally advanced pancreatic cancer (LAPC). The primary aim of this study was to evaluate survival of LAPC patients after IRE prior to chemotherapy. The secondary aim was to examine the complication rates. Patients and Methods: Twenty-four patients with LAPC were included and treated with percutaneous ultrasound-guided IRE under general anesthesia. Survival data from the National Quality Registry for Pancreatic and Periampullary Cancer for LAPC during the same period were used for comparison. Results: The median survival after diagnosis was 13.3 months in the IRE group compared to 9.9 months in the registry group (p=0.511). Six patients had a severe complication after IRE treatment. Conclusion: No obvious gain in survival was observed with IRE as the first line treatment of LAPC and IRE was associated with severe complications. This study does not support percutaneous IRE in this setting.